in vivo News and Research

RSS

Zyngenia completes $15M Series A financing extension from NEA

Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.

8 Sep 2010

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Trius Therapeutics, Inc. announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate torezolid phosphate (TR-701), will be presented in poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston September 12-15.

8 Sep 2010

Researchers discover tolerance mechanism in chronic morphine treatment

Researchers from Mount Sinai School of Medicine have discovered a major mechanism underlying the development of tolerance to chronic morphine treatment. The discovery may help researchers find new therapies to treat chronic pain, and reduce tolerance and side effects associated with morphine use. The findings are published in the July 20th issue of Science Signaling.

8 Sep 2010

Bruker launches Icon desktop MRI systems at 2010 World Molecular Imaging Congress

At the 2010 World Molecular Imaging Congress in Kyoto, Bruker Corporation today announces the introduction of the Icon™, a new easy-to-use 1 Tesla desktop MRI scanner that combines simplicity with compact dimensions, in order to bring preclinical magnetic resonance imaging (MRI) within reach for a broader range of molecular imaging laboratories.

7 Sep 2010

Medtronic announces international launch of Resolute Integrity Stent System

Medtronic, Inc. (NYSE: MDT), announces the CE (Conformite Europeene) mark and international launch of the Resolute Integrity Stent System for the treatment of coronary artery disease, a leading cause of death and poor quality of life.

7 Sep 2010

Rexahn Pharmaceuticals publishes research article on RX-8243 anti-tumor activity

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Bioorganic & Medicinal Chemistry Letters on the anti-tumor activity of RX-8243 and its analogues.

3 Sep 2010

Evotec AG announces Closing conditions to acquire DeveloGen

Evotec AG today announced the Closing of the agreement to acquire DeveloGen as announced in detail on 14 July 2010.

2 Sep 2010

Cellerant Therapeutics signs contract with BARDA to develop CLT-008 therapy for ARS

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has signed a contract valued at up to $153 million over five years with the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, to develop CLT-008, a cellular therapy for the treatment of Acute Radiation Syndrome (ARS).

2 Sep 2010

Naurex announces GLYX-13 molecule recognized in “Top 10 to Watch" list for depression treatment

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that its clinical stage candidate for the treatment of depression, GLYX-13, and its second-generation NRX-1050 series have been selected for inclusion on Windhover's list of the "Top 10 Most Interesting Neuroscience Projects to Watch."

31 Aug 2010

Researchers identify molecule to slow down dysfunctional immune response in hemorrhagic shock

Researchers have isolated a molecule, small enough to be used as a drug, that can shut down a dysfunctional immune response that causes deadly hemorrhagic shock, results in delayed death of heart attack patients, promotes rejection of transplanted organs and destroys joints in patients with rheumatoid arthritis, according to a paper published in Molecular Immunology.

27 Aug 2010

Phase 1 CRLX101 clinical study paves way for promising innovations in cancer therapy: Cerulean Pharma

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.

26 Aug 2010

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Afferent Pharmaceuticals, a clinical-stage biopharmaceutical company developing first-in-class, small molecule compounds that target P2X3 receptors, today announced preclinical in vivo results demonstrating that an investigational P2X3 receptor antagonist reduced experimentally induced bladder hyperactivity.

26 Aug 2010

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

Alnylam Pharmaceuticals, Inc.,a leading RNAi therapeutics company, announced today that it will make a total of 16 oral presentations at the American Chemical Society (ACS) Fall 2010 240th National Meeting & Exposition being held in Boston, Mass. from August 22-26, 2010.

24 Aug 2010

APC dysfunction prevents synapse function required for learning, memory: Study

A clue to the causes of autism and mental retardation lies in the synapse, the tiny intercellular junction that rapidly transfers information from one neuron to the next. According to neuroscientists at Tufts University School of Medicine, with students from the Sackler School of Graduate Biomedical Sciences at Tufts, a protein called APC plays a key role in synapse maturation, and APC dysfunction prevents the synapse function required for typical learning and memory.

23 Aug 2010

Scientists identify compound to treat Chagas' disease

A new compound may offer an effective drug candidate against the deadly tropical infection, Chagas' disease say researchers from Brazil. They report their findings in the August 2010 issue of the journal Antimicrobial Agents and Chemotherapy.

21 Aug 2010

Cetero Research expands Clinical Dermatology and Transdermal Delivery System services

Cetero Research, the leading early stage contract research organization (CRO), today announced the expansion of multiple Clinical Dermatology and Transdermal Delivery System (TDDS) services to four Cetero clinical facilities.

20 Aug 2010

Cluster-coated implant strengthens attachment of joint-replacement implant with bone

Researchers have developed an improved coating technique that could strengthen the connection between titanium joint-replacement implants and a patients' own bone. The stronger connection created by manipulating signals the body's own cells use to encourage growth could allow the implants to last longer.

19 Aug 2010

Zebrafish-yeast approach for studying copper deficiency, complex multifactorial diseases

Copper deficiency diseases can be devastating. Symptoms can range from crippling neurological degeneration in Menkes disease ,a classic copper deficiency disease to brittle bones, anaemia and defective skin pigmentation in gastric bypass patients. Unfortunately, very little is known about how the body uses this essential nutrient. Knowing that melanocytes (the cells that give rise to hair, skin and eye pigmentation) are dramatically affected by the effects of copper deficiency, Elizabeth Patton from the University of Edinburgh, UK, and other colleagues from UK and US based labs decided to find out how melanocytes metabolise copper.

17 Aug 2010

Researchers develop method to predict lifetime of implants

Extra-hard coatings made from diamond-like carbon (DLC) extend the operating lifetime of tools and components. In artificial joints, however, these coatings often fail because they detach. Empa researchers found out why - and developed methods to both make the interface between the DLC layer and the metal underneath corrosion-resistant and to predict the lifetime of the implants.

16 Aug 2010

Mercator signs license agreement with MD Anderson Cancer Center and closes $2.0 million seed round

Mercator Therapeutics, the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs, today announced the signing of a license agreement with The University of Texas MD Anderson Cancer Center and the closing of a $2.0 million seed round.

13 Aug 2010

in vivo News and Research

Zyngenia completes $15M Series A financing extension from NEA

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Researchers discover tolerance mechanism in chronic morphine treatment

Bruker launches Icon desktop MRI systems at 2010 World Molecular Imaging Congress

Medtronic announces international launch of Resolute Integrity Stent System

Rexahn Pharmaceuticals publishes research article on RX-8243 anti-tumor activity

Evotec AG announces Closing conditions to acquire DeveloGen

Cellerant Therapeutics signs contract with BARDA to develop CLT-008 therapy for ARS

Naurex announces GLYX-13 molecule recognized in “Top 10 to Watch" list for depression treatment

Researchers identify molecule to slow down dysfunctional immune response in hemorrhagic shock

Phase 1 CRLX101 clinical study paves way for promising innovations in cancer therapy: Cerulean Pharma

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

APC dysfunction prevents synapse function required for learning, memory: Study

Scientists identify compound to treat Chagas' disease

Cetero Research expands Clinical Dermatology and Transdermal Delivery System services

Cluster-coated implant strengthens attachment of joint-replacement implant with bone

Zebrafish-yeast approach for studying copper deficiency, complex multifactorial diseases

Researchers develop method to predict lifetime of implants

Mercator signs license agreement with MD Anderson Cancer Center and closes $2.0 million seed round

eBook: Using iPSCs models for human disease research and drug discovery eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News